Brookline initiated coverage of Y-mAbs Therapeutics (YMAB) with a Buy rating and $17 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on YMAB:
- Y-mAbs Therapeutics initiated with an Outperform at Oppenheimer
- Y-mAbs Reports Third Quarter 2024 Financial Results
- Morning Movers: Expedia, Airbnb moving in opposite directions after results
- Y-mAbs Therapeutics reports Q3 EPS (16c), consensus (16c)
- Y-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
